» Articles » PMID: 18593982

Activation of Notch Signaling in a Xenograft Model of Brain Metastasis

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2008 Jul 3
PMID 18593982
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The potential of metastasis can be predicted from clinical features like tumor size, histologic grade, and gene expression patterns. We examined the whole-genome transcriptomic profile of a xenograft model of breast cancer to understand the characteristics of brain metastasis.

Experimental Design: Variants of the MDA-MB-435 cell were established from experimental brain metastases. The LvBr2 variant was isolated from lesions in a mouse injected in the left ventricle of the heart, and these cells were used for two cycles of injection into the internal carotid artery and selection of brain lesions, resulting in the Br4 variant. To characterize the different metastatic variants, we examined the gene expression profile of MDA-MB-435, LvBr2, and Br4 cells using microarrays.

Results: We could identify 2,016 differentially expressed genes in Br4 by using the F test. Various metastasis-related genes and a number of genes related to angiogenesis, migration, tumorigenesis, and cell cycle were differentially expressed by the Br4 cells. Notably, the Notch signaling pathway was activated in Br4, with increased Jag2 mRNA, activated Notch intracellular domain, and Notch intracellular domain/CLS promoter-luciferase activity. Br4 cells were more migratory and invasive than MDA-MB-435 cells in collagen and Matrigel Transwell assays, and the migration and invasion of Br4 cells were significantly inhibited by inactivation of Notch signaling using DAPT, a gamma-secretase inhibitor, and RNA interference-mediated knockdown of Jagged 2 and Notch1.

Conclusions: Taken together, these results suggest that we have isolated variants of a human cancer cell line with enhanced brain metastatic properties, and the activation of Notch signaling might play a crucial role in brain metastasis.

Citing Articles

Drug Treatment Direction Based on the Molecular Mechanism of Breast Cancer Brain Metastasis.

Zhang Y, Shang H, Zhang J, Jiang Y, Li J, Xiong H Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006075 PMC: 11859690. DOI: 10.3390/ph18020262.


Navigating the Blood-Brain Barrier: Challenges and Therapeutic Strategies in Breast Cancer Brain Metastases.

Terceiro L, Ikeogu N, Lima M, Edechi C, Nickel B, Fischer G Int J Mol Sci. 2023; 24(15).

PMID: 37569410 PMC: 10418424. DOI: 10.3390/ijms241512034.


Genomics of Breast Cancer Brain Metastases: A Meta-Analysis and Therapeutic Implications.

Nguyen T, Hamdan D, Angeli E, Feugeas J, Le Q, Pamoukdjian F Cancers (Basel). 2023; 15(6).

PMID: 36980614 PMC: 10046845. DOI: 10.3390/cancers15061728.


Brain metastasis in breast cancer: focus on genes and signaling pathways involved, blood-brain barrier and treatment strategies.

Chhichholiya Y, Ruthuparna M, Velagaleti H, Munshi A Clin Transl Oncol. 2023; 25(5):1218-1241.

PMID: 36897508 DOI: 10.1007/s12094-022-03050-z.


An HLA-G/SPAG9/STAT3 axis promotes brain metastases.

Bassey-Archibong B, Rajendra Chokshi C, Aghaei N, Kieliszek A, Tatari N, McKenna D Proc Natl Acad Sci U S A. 2023; 120(8):e2205247120.

PMID: 36780531 PMC: 9974476. DOI: 10.1073/pnas.2205247120.